North America U.S. In Vitro Diagnostics (IVD) Market Analysis, 2025-2035
The North America U.S. In Vitro Diagnostics (IVD) Market encompasses a range of diagnostic tests performed on biological samples to detect diseases, conditions, or infections. This market is pivotal in disease prevention, management, and treatment, offering real-time clinical insights that improve patient care outcomes. The sector includes reagents, kits, instruments, software, services, and is applied in areas such as infectious diseases, diabetes, and oncology, leveraging technologies like immunoassays, molecular diagnostics, and clinical chemistry. As healthcare evolves towards precision medicine, demand for IVD products continues to surge, with robust contributions from hospital labs, academic centers, and point-of-care solutions. Key players drive technological advancement, innovation, and expanded product portfolios to address emerging health burdens and diagnostic needs.
Latest Market Dynamics
Key Drivers
- Rising prevalence of chronic and infectious diseases: Increasing cases of diabetes, cancer, and infectious diseases drive demand for advanced diagnostic tools. Companies like Roche Diagnostics are expanding their IVD portfolio to address this growing need in North America.
- Technological advancements in molecular diagnostics: Innovations in PCR, NGS, and immunoassays enhance sensitivity, speed, and accuracy of diagnostics. Abbott Laboratories, for example, launched Alinity™ m, a state-of-the-art molecular platform to streamline laboratory operations and accelerate viral detection.
Key Trends
- Shift towards point-of-care (POC) testing: Rapid, easy-to-use IVD kits enable quicker clinical decisions in diverse healthcare settings. Siemens Healthineers is investing in POC diagnostics to allow decentralized testing for improved patient care.
- Integration of artificial intelligence (AI): AI-powered IVD tools support automated analysis, predictive diagnostics, and personalized medicine approaches. Thermo Fisher Scientific incorporates AI in diagnostic solutions, optimizing result interpretation and workflow management.
Key Opportunities
- Expansion into untapped markets and home-based/self-testing: Increasing consumer awareness and preference for home-based testing open new growth avenues. Hologic, Inc. has been expanding its self-testing portfolio for infectious disease diagnostics.
- Development of multiplex diagnostic platforms: Simultaneous detection of multiple pathogens or biomarkers in a single run is a key area for growth. Bio-Rad Laboratories recently introduced multiplex molecular kits for respiratory and infectious diseases.
Key Challenges
- Stringent regulatory compliance and slow approval process: Ensuring product safety, efficacy, and regulatory alignment delays new product launches. Qiagen N.V. faces challenges accelerating regulatory approvals for novel assays in the U.S. market.
- Data security and interoperability: Protecting sensitive patient data and ensuring seamless data integration across different IT platforms remains complex. Becton, Dickinson and Company (BD) is actively working to enhance data interoperability and cybersecurity in its IVD ecosystem.
Key Restraints
- High costs of advanced diagnostics: Capital investments required for cutting-edge diagnostic equipment limit adoption in resource-constrained settings. Smaller labs may find Sysmex Corporation’s hematology analyzers financially inaccessible.
- Scarcity of skilled laboratory professionals: Limited pool of trained technicians and diagnosticians hampers expansion and efficient use of sophisticated IVD tests. Ortho Clinical Diagnostics is offering remote-training solutions to address workforce shortages in lab diagnostics.
IVD Market Share by Type, 2025
In 2025, reagents & kits take the largest share of the North America U.S. IVD market, owing to their recurring use in high-volume operations and their essential role in diagnostic workflows. Instruments account for a significant share as advanced analyzers are vital for complex tests, while software & services gain momentum through digital transformation and cloud integration initiatives. The focus on laboratory automation, alongside demand for reliable consumables and calibrators, is shaping procurement decisions across hospitals and labs.
IVD Market Share by Application, 2025
By application, infectious diseases represent the largest share of the North America U.S. IVD market in 2025 due to a persistent need for fast, accurate diagnostics in light of global health threats like COVID-19 and emerging pathogens. Diabetes and oncology applications are also significant contributors, reflecting rising prevalence and prioritization of early detection in clinical protocols. Enhanced focus on population health management and personalized medicine further propels demand for robust diagnostic assays.
North America U.S. IVD Market Revenue (USD Million), 2020-2035
Market revenue for the North America U.S. IVD sector shows robust growth between 2020 and 2035. Starting around USD 16,700 Million in 2020, revenues are projected to increase steadily with a CAGR of around 6.2%, reaching approximately USD 47,800 Million by 2035. Expansion is fueled by the growing burden of chronic diseases, technological evolution in diagnostics, and proactive healthcare infrastructure investments across the region. The U.S. maintains leadership, with Canada and Mexico exhibiting promising growth trends.
IVD Market Year-on-Year Growth Rate (%), 2020-2035
Year-on-Year (YOY) growth for the IVD market in North America shows moderate to strong upward movement. The market witnessed a YOY spike in 2020-2021 owing to pandemic-driven demand, stabilizing to healthy single-digit rates through 2025. Ongoing trends in laboratory automation, chronic disease management, and POC diagnostic adoption are expected to sustain a 5-7% annual growth rate over the period, with new technology cycles further stimulating the market post-2030.
Market Share by Region, 2025
The United States dominates the North America U.S. IVD market in 2025 with a commanding 83% share, attributed to advanced infrastructure, high healthcare expenditure, and leading company headquarters. Canada follows with a 10% market share, benefitting from increasing R&D activities and government initiatives. Mexico, with a 7% share, shows steady uptake of IVD solutions as public health investments rise and private labs expand diagnostic capacities.
Market Share by Key Players, 2025
In 2025, Abbott Laboratories holds the largest player share at 23%, leveraging its broad diagnostics portfolio and robust distribution network. Roche Diagnostics claims 19% driven by dedicated molecular platforms and infectious disease assays, while Siemens Healthineers secures 15% owing to their extensive solutions in clinical chemistry and POC. Other notable contributors include Danaher Corporation and Thermo Fisher Scientific, each innovating to gain incremental market share through strategic partnerships and acquisitions.
Market Share by Buyer Type, 2025
Hospital laboratories constitute the primary buyers in the 2025 IVD market, representing 41% of total procurement. Point-of-care (POC) testing accounts for 28%, reflecting the paradigm shift towards rapid and decentralized testing. Academic & medical schools make up 15%, underlining their critical role in clinical research and training. Patient self-testing is also gaining momentum, as individuals seek greater involvement in personal health management.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 23000 |
| Regions | US, Canada, Mexico |
| Segments | By Type: Reagents & Kits, Instruments, Software & Services, Consumables, Calibrators & Controls, Accessories; By Application: Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases |
| Players | Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Becton Dickinson and Company (BD), Sysmex Corporation, bioMérieux SA, Ortho Clinical Diagnostics, Hologic Inc., Agilent Technologies, Qiagen N.V., Illumina Inc., PerkinElmer Inc. |
Key Recent Developments
- June 2024: Abbott Laboratories introduces an upgraded Alinity™ m molecular platform for multi-pathogen detection, accelerating infectious disease diagnostics across North America.
- July 2024: Roche Diagnostics receives emergency use authorization from the FDA for a new multiplex PCR assay targeting respiratory viruses.
- August 2024: Siemens Healthineers partners with Mayo Clinic to co-develop AI-powered IVD tools for precision oncology diagnostics.
- September 2024: Thermo Fisher Scientific acquires a digital health company to strengthen its cloud-based diagnostic services portfolio.
- October 2024: Becton, Dickinson and Company (BD) launches a nationwide digital training initiative to address laboratory workforce shortages and enhance operational efficiency.
